CXCL9 and neuroblastoma: Our results showed that the combination of anti-GD2 immunotherapy with MβCD significantly enhanced chemokine CXCL9/10 expression and CD8+ T-cell infiltration, suggesting that combination therapy significantly enhances the response to anti-GD2 immunotherapy in NB.